Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Type I Diabetes III: Clinical Manifestations

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...

Hypoglycemia

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Follicular mucinosis.

Indian journal of dermatology, venereology and leprology·2010

Same journal

Severe combined immunodeficiency (SCID) with pigmentary mosaicism: A coincidental occurrence in a child.

Indian journal of dermatology, venereology and leprology·2026

Same journal

Agminated multifocal eruptive lobular capillary haemangiomas - An uncommon presentation.

Indian journal of dermatology, venereology and leprology·2026

Same journal

Patch testing in India: Are we missing clinically relevant allergens?

Indian journal of dermatology, venereology and leprology·2026

Same journal

Double-loading technique for improved suspension retention on the recipient site in non-cultured epidermal cell suspension (NCES).

Indian journal of dermatology, venereology and leprology·2026

Same journal

Late-onset metastatic melanoma arising from a medium-sized congenital melanocytic naevus.

Indian journal of dermatology, venereology and leprology·2026

Same journal

Custom-compounded glycine-proline jelly for ulcers in prolidase deficiency.

Indian journal of dermatology, venereology and leprology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 8, 2026

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

Glucagonoma syndrome.

V L Aswani¹, R H Malkani

¹Department of Dermatology, Jaslok Hospital and Research Centre, 15, Dr G Deshmukh Marg, Mumbai-400026, India.

Indian Journal of Dermatology, Venereology and Leprology

|October 16, 2010

Summary

This summary is machine-generated.

This case report details a glucagonoma, a rare tumor. The patient experienced skin erosions, bullous dermatitis, glucose intolerance, and weight loss due to the tumor.

More Related Videos

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Related Experiment Videos

Last Updated: Jun 8, 2026

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Area of Science:

Endocrinology
Oncology
Dermatology

Background:

Glucagonoma is a rare neuroendocrine tumor originating from alpha cells of the pancreas.
It is characterized by excessive glucagon secretion, leading to distinct clinical manifestations.
The typical presentation includes the glucagonoma syndrome, encompassing dermatitis, diabetes, and weight loss.

Purpose of the Study:

To present a clinical case of glucagonoma.
To highlight the characteristic dermatological and metabolic symptoms associated with this rare tumor.
To emphasize the importance of considering glucagonoma in the differential diagnosis of unexplained skin lesions and metabolic disturbances.

Main Methods:

Case presentation of a patient diagnosed with glucagonoma.
Review of clinical findings including dermatological examination and metabolic assessment.
Diagnostic workup including imaging and biochemical tests.

Main Results:

The patient presented with erosions, crusts, and bullous dermatitis.
Glucose intolerance and significant weight loss were key metabolic findings.
Diagnosis confirmed as glucagonoma.

Conclusions:

Glucagonoma can manifest with significant dermatological and metabolic abnormalities.
Early recognition of the glucagonoma syndrome is crucial for timely diagnosis and management.
This case underscores the importance of a multidisciplinary approach in managing rare neuroendocrine tumors.